A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02922764
Recruitment Status : Recruiting
First Posted : October 4, 2016
Last Update Posted : March 2, 2018
Information provided by (Responsible Party):
Rgenix, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 2019
  Estimated Study Completion Date : October 2019